Stocks
FocalTherics Confirms 2026 HIFU Revenue, Secures $40M Equity
FocalTherics (FOCL) reiterates its $50M-$54M 2026 HIFU revenue outlook and successfully closes a $40M equity offering, signaling a transformative period for the...
#medical technology 3 articles
Stocks
TELA Bio Projects 8% Revenue Growth for 2026, Guides Q2 at $20M
TELA Bio (TELA) forecasts at least 8% revenue growth for 2026 and guides Q2 revenue to about $20.0 million, citing early success...
Stocks
Beta Bionics Projects $131M Revenue, Boosts Margin Outlook
Beta Bionics forecasts $131M-$136M in 2026 revenue and raises its gross margin outlook to 57.5%-59.5%, signaling strong financial projections.